Etodesnitazene

Last updated

Desnitroetonitazene
Etodesnitazene.svg
Legal status
Legal status
Identifiers
  • 2-[2-[(4-Ethoxyphenyl)methyl]benzimidazol-1-yl]-N,N-diethylethanamine
CAS Number
PubChem CID
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
Formula C22H29N3O
Molar mass 351.494 g·mol−1
3D model (JSmol)
  • CCN(CC)CCN1C2=CC=CC=C2N=C1CC3=CC=C(C=C3)OCC
  • InChI=1S/C22H29N3O/c1-4-24(5-2)15-16-25-21-10-8-7-9-20(21)23-22(25)17-18-11-13-19(14-12-18)26-6-3/h7-14H,4-6,15-17H2,1-3H3
  • Key:BMLPNUNXHUGDOI-UHFFFAOYSA-N

Etodesnitazene (also known as desnitroetonitazene, etazen, etazene, and etazone) is a benzimidazole-derived opioid analgesic drug, which was originally developed in the late 1950s alongside etonitazene and a range of related derivatives. [1] It is many times less potent than etonitazene itself, but still 70 times more potent than morphine in animal studies. Corresponding analogues where the N,N-diethyl group is replaced by piperidine or pyrrolidine rings also retain significant activity (10 times and 20 times morphine, respectively). [2] Etodesnitazene has been sold as a designer drug, [3] first being identified in both Poland and Finland in March 2020. [4] [5]

Contents

United Kingdom

Since 15 January 2025 it is covered by the UK's generic definition on 2-benzyl benzimidazole derived opioids [6] [7] because it contains the 2-(2-benzyl-benzimidazol-1-yl)ethanamine backbone with only the following modification: [8]

See also

References

  1. ↑ Ujváry I, Christie R, Evans-Brown M, Gallegos A, Jorge R, de Morais J, Sedefov R (April 2021). "DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles". ACS Chemical Neuroscience. 12 (7): 1072–1092. doi:10.1021/acschemneuro.1c00037. PMID   33760580. S2CID   232356192.
  2. ↑ Hunger A, Kebrle J, Rossi A, Hoffmann K (1960). "Benzimidazol-Derivate und verwandte Heterocyclen. II. Synthese von 1-Aminoalkyl-2-benzyl-benzimidazolen". Helvetica Chimica Acta (in German). 43 (3): 800–809. doi:10.1002/hlca.19600430323.
  3. ↑ Siczek M, Zawadzki M, Siczek M, Chłopaś-Konowałek A, Szpot P (2020). "Etazene (N,N-diethyl-2-{[(4-ethoxyphenyl)methyl]-1H-benzimidazol-1-yl}-ethan-1-amine (dihydrochloride)): a novel benzimidazole opioid NPS identified in seized material: crystal structure and spectroscopic characterization". Forensic Toxicology. doi: 10.1007/s11419-020-00552-9 . ISSN   1860-8973.
  4. ↑ Siczek M, Zawadzki M, Siczek M, Chłopaś-Konowałek A, Szpot P (January 2021). "Etazene (N,N-diethyl-2-{[(4-ethoxyphenyl)methyl]-1H-benzimidazol-1-yl}-ethan-1-amine (dihydrochloride)): a novel benzimidazole opioid NPS identified in seized material: crystal structure and spectroscopic characterization". Forensic Toxicology. 39 (1): 146–155. doi: 10.1007/s11419-020-00552-9 . ISSN   1860-8965.
  5. ↑ "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.
  6. ↑ "The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2024 and The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment) (No. 2) Regulations 2024". GOV.UK. Retrieved 2025-05-30.
  7. ↑ "Britain working at pace to curb rising synthetic drugs threat". GOV.UK. Retrieved 2025-06-12.
  8. ↑ "The Misuse of Drugs Regulations 2001 (2024 Order (No. 2))". Legislation.gov.uk. HM Government (UK). Retrieved 11 August 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.